Edit

Biosense Webster

https://www.biosensewebster.com/

Last activity: 04.11.2024

Active - Reference to LINX® Reflux Management System

Categories: CareEquipmentFamilyHardwareHealthTechInformationManufacturingMedTechScienceTools

Biosense Webster, Inc. is the global leader in the science of diagnosing and treating heart rhythm disorders. The company partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide. Biosense Webster is part of the Johnson & Johnson Family of Companies. More information can be found at www.biosensewebster.com.

Followers

5.87K

Followers

39.48K

Mentions

Location: United States, California, Irvine

Employees: 1001-5000

Founded date: 1998

Investors 1

Date	Name	Website
-	XT Hi-Tech	xthitech.c...

Mentions in press and media 20

Date	Title	Description
04.11.2024	Boston Scientific to acquire Cortex and its cardiac mapping tech	Boston Scientific (NYSE: BSX) announced today that it will purchase Ajax Health’s Cortex and its FDA-cleared OptiMap system to guide physicians performing ablation procedures to treat AFib Financial terms of the deal were not disclosed. Bos...
08.05.2024	Biosense Webster Launches New Version of CARTO™ 3 Electro-Anatomical Mapping System	New CARTO™ 3 System Version 8 software introduces machine learning capabilities Increases efficiency, reproducibility, and accuracyi in the electro-anatomical maps electrophysiologists use in catheter ablation procedures IRVINE, Calif., May...
06.12.2022	Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation	A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Dec. 6, 2022 /PRNewswire/ -- Biosense Webster, Inc., par...
17.11.2022	Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation	A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ -- Biosense Webster, Inc., pa...
11.11.2013	$15M boost should push heart mapping firm CardioInsight across U.S. commercialization finish line	Doctors may use cardiac mapping to help diagnose and treat electrical abnormalities of the heart, like arrhythmia and heart failure. Currently it’s done in an EP lab, where technicians insert catheters into various locations around the pati...
04.05.2011	AtriCure: Atrial fibrillation trial to be ‘inflection point’ for business	Drachman spoke with analysts in a conference call discussing AtriCure’s first-quarter financial results. The company’s quarterly loss narrowed to $1.3 million from $2 million in the year-earlier quarter. Last quarter, AtriCure reported its ...
17.02.2011	AtriCure climbs into the black for the first time	Cardiac surgical device maker AtriCure Inc. (NSDQ:ATRC) has reported its first-ever profitable quarter as sales of its AtriClip device continue to climb. The company’s fourth-quarter earnings were scant, $11,500, but still far exceeded the ...
16.02.2011	AtriCure reports first-ever profitable quarter	The majority of the company’s revenue, $13.3 million, came from the U.S. The AtriClip is a clip used during heart surgery to exclude the left atrial appendage. This exclusion helps protect atrial fibrillation patients from strokes. AtriClip...
04.01.2011	AtriCure upgraded to ‘Buy’ by Roth Capital, target price raised 30%	Roth also sees growth potential in AtriCure due to several milestones the West Chester, Ohio, company is working to accomplish. One is simply increasing sales of its AtriClip device, which is a clip used during heart surgery to exclude the ...
04.01.2011	Roth Capital upgrades AtriCure stock	Investment bank Roth Capital Partners upgraded shares of AtriCure Inc. (NSDQ:ATRC) to “Buy” and raised its target price by nearly 30 percent. AtriCure, a cardiac surgical device maker, will enter “a new phase” during the next two years in w...
02.12.2010	Atricure enrolls first patient in atrial fibrillation trial	Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ...
11.05.2010	AtriCure wins FDA nod, posts positive Q1 results	By Mary Vanac Cardiac ablation systems maker AtriCure Inc. (NSDQ:ATRC) won a conditional nod from the Food & Drug Administration to evaluate the safety and efficacy of a hybrid procedure to treat patients with persistent forms of atrial...
10.05.2010	AtriCure gets FDA nod to try hybrid atrial fibrillation procedure	Atricure will try a “dual epicardial/endocardial procedure” (DEEP) on 30 patients at up to five U.S. medical the company said. Enrollment is expected to begin in the second half of the year. The hybrid procedure combines surgical and cathet...
28.01.2010	Study another positive sign for catheter ablation advocates	Medical device manufacturers seeking regulatory clearances to expand catheter ablation as a treatment for atrial fibrillation got a boost from a new study published in the Journal of the American Medical Assn. The 19-center study compared t...
-	AtriCure gets FDA nod to try hybrid atrial fibrillation procedure	Updated 8:10 p.m., May 10, 2010. Atricure Inc. (NASDAQ: ATRC), the maker of cardiac surgical ablation systems, has received a conditional nod from the Food and Drug Administration (FDA) to evaluate the safety and efficacy of a hybrid proced...
-	$15M boost should push heart mapping firm CardioInsight across U.S. commercialization finish line	CardioInsight Technologies said today that it had secured “long-term strategic financing” that will allow it to complete ongoing clinical trials in Europe, advance product development programs and pursue regulatory clearance for its cardiac...
-	AtriCure upgraded to ‘Buy’ by Roth Capital, target price raised 30%	Investment bank Roth Capital Partners has upgraded shares of AtriCure Inc. (NASDAQ:ATRC) to “Buy” and raised its target price by nearly 30 percent. AtriCure, a cardiac surgical device maker, will enter “a new phase” during the next two year...
-	AtriCure: Atrial fibrillation trial to be ‘inflection point’ for business	The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure’s (NASDAQ:ATRC) U.S. business, its CEO said. The pivota...
-	AtriCure reports first-ever profitable quarter	Cardiac surgical device maker AtriCure Inc. (NASDAQ:ATRC) has reported its first-ever profitable quarter as sales of its AtriClip device continue to climb. The company’s fourth-quarter earnings were scant, $11,500, but still far exceeded th...
-	Atricure enrolls first patient in atrial fibrillation trial	Cardiac medical device maker AtriCure Inc. (NASDAQ:ATRC) has enrolled the first patient in a clinical trial designed to test a hybrid procedure on patients with persistent atrial fibrillation, a condition marked by irregular heart rhythm. T...

Biosense Webster

Investors 1

Mentions in press and media 20

Reviews 0